These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 21704105)

  • 1. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine.
    Gimenez-Sanchez F; Kieninger DM; Kueper K; Martinon-Torres F; Bernaola E; Diez-Domingo J; Steul K; Juergens C; Gurtman A; Giardina P; Liang JZ; Gruber WC; Emini EA; Scott DA;
    Vaccine; 2011 Aug; 29(35):6042-8. PubMed ID: 21704105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
    Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
    Martinón-Torres F; Gimenez-Sanchez F; Gurtman A; Bernaola E; Diez-Domingo J; Carmona A; Sidhu M; Sarkozy DA; Gruber WC; Emini EA; Scott DA;
    Pediatr Infect Dis J; 2012 Apr; 31(4):392-9. PubMed ID: 22301472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
    Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
    J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants.
    Kosalaraksa P; Thisyakorn U; Benjaponpitak S; Chokephaibulkit K; Santos-Lima E
    Int J Infect Dis; 2011 Apr; 15(4):e249-56. PubMed ID: 21334243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study.
    Tapiéro B; Halperin SA; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee AW; Li M; Tomovici A
    Pediatr Infect Dis J; 2013 Jan; 32(1):54-61. PubMed ID: 23241989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus type b conjugate vaccine when administered concurrently with a pneumococcal conjugate vaccine: a randomized, open-label, phase 3 study.
    Bernstein HH; Noriega F;
    Vaccine; 2011 Mar; 29(11):2212-21. PubMed ID: 20609398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity, Safety and Reactogenicity of a Booster Dose of the 10-Valent Pneumococcal Nontypeable H. influenzae Protein D Conjugate Vaccine Coadministered With DTPa-IPV-Hib in Dutch Children: A Randomized Controlled Trial.
    van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA
    Pediatr Infect Dis J; 2016 Jul; 35(7):e206-19. PubMed ID: 27097348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Gurtman A; Girgenti D; Reisinger K; Johnson A; Pride MW; Patterson S; Devlin C; Gruber WC; Emini EA; Scott DA
    Pediatr Infect Dis J; 2013 Apr; 32(4):383-8. PubMed ID: 23104129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B conjugate combination vaccine (Pentaxim) with hepatitis B vaccine.
    Dutta AK; Verghese VP; Pemde HK; Mathew LG; Ortiz E
    Indian Pediatr; 2009 Nov; 46(11):975-82. PubMed ID: 19955579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
    Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
    Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
    Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.
    Diaz-Mitoma F; Halperin SA; Tapiero B; Hoffenbach A; Zappacosta PS; Radley D; Bradshaw S; Martin JC; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2011 Feb; 29(6):1324-31. PubMed ID: 21134456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
    Halperin SA; King J; Law B; Mills E; Willems P
    Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.